Michael C. Welsh
Presidente presso Almasa Capital, Inc.
Profilo
Michael C.
Welsh is currently the President of Almasa Capital, Inc. He was previously the Chairman of Micralyne, Inc. and held director positions at Biomira, Inc. and Cascadian Therapeutics LLC.
He was also a partner at Welsh & Co. Mr. Welsh received an undergraduate degree from the University of Alberta.
Posizioni attive di Michael C. Welsh
Società | Posizione | Inizio |
---|---|---|
Almasa Capital, Inc. | Presidente | - |
Precedenti posizioni note di Michael C. Welsh
Società | Posizione | Fine |
---|---|---|
CASCADIAN THERAPEUTICS INC (USA) | Direttore/Membro del Consiglio | 11/12/2008 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | Direttore/Membro del Consiglio | 11/12/2007 |
Welsh & Co. | Corporate Officer/Principal | - |
Micralyne, Inc.
Micralyne, Inc. Industrial MachineryProducer Manufacturing Micralyne, Inc. develops and manufactures micro fabricated products. It offers wafer level packaging, die level packaging, silicon optical bench and spatial light valve. The firm’s services are used in the areas of microfluidics and MEMs sensors. The company was founded in 1982 and is headquartered in Edmonton, Canada. | Presidente | - |
Formazione di Michael C. Welsh
University of Alberta | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | Health Services |
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Almasa Capital, Inc. | |
Micralyne, Inc.
Micralyne, Inc. Industrial MachineryProducer Manufacturing Micralyne, Inc. develops and manufactures micro fabricated products. It offers wafer level packaging, die level packaging, silicon optical bench and spatial light valve. The firm’s services are used in the areas of microfluidics and MEMs sensors. The company was founded in 1982 and is headquartered in Edmonton, Canada. | Producer Manufacturing |
Welsh & Co. |
- Borsa valori
- Insiders
- Michael C. Welsh